23.03.2026 • Topics

Aligning Artificial Intelligence and Laboratory Execution in Drug Discovery

From In Silico Design to In Vitro Impact

Yann Gaston-Mathé, Iktos

Photo
© Iktos

Artificial intelligence is transforming molecular design, but synthesis remains the limiting step in drug discovery. To translate computational advances into real productivity gains, organizations must better align digital design with laboratory execution. AI-driven orchestration provides a practical framework to coordinate design, synthesis, and testing within existing R&D infrastructures, accelerating the transition from in silico hypotheses to in vitro validation and improving the productivity of the DMTA cycle.

The Acceleration Paradox

Artificial intelligence is reshaping how molecules are conceived. Generative models can now explore vast regions of chemical space, proposing and optimizing candidate structures with unprecedented speed.

Read more with free registration

Register now for free and get full access to all exclusive articles from chemanager-online.com. With our newsletter we regularly send you top news from the chemistry industry as well as the latest e-issue.

Sign in or register

Company

Logo:

Iktos AI

65 rue de Prony
75017 Paris
France

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read